B and T lymphocytes (B and T cells)

B and T lymphocytes are the primary cellular mediators of the adaptive immune system, responsible for recognizing and responding to specific antigens with high precision. B cells provide humoral immunity by differentiating into plasma cells that secrete antibodies, while T cells provide cell-mediated immunity through direct cytotoxic activity or by orchestrating the broader immune response via cytokine secretion (StatPearls, 2023). In clinical medicine, these cells are central to the pathogenesis of various conditions, including lymphoid malignancies (leukemias and lymphomas), autoimmune disorders like rheumatoid arthritis, and the rejection of transplanted organs (NIH, 2022). While B and T lymphocytes represent a cellular category rather than a single molecular target, they are the focus of diverse pharmacological interventions. These include monoclonal antibodies targeting surface markers (e.g., CD20 on B cells), small molecule inhibitors of signaling cascades (e.g., TCR or BCR signaling), and modern immunotherapies like CAR-T cells and checkpoint inhibitors that leverage or modulate lymphocyte activity to treat cancer (PubMed, 2021). Understanding the distinct subsets and functional states of these lymphocytes is essential for the development of targeted biologics and precision medicine in immunology and oncology.

Other names

LymphocytesAdaptive immune cellsB cellsT cellsAntigen-specific lymphocytes

Therapeutic strategies involving B and T lymphocytes typically involve the depletion of specific cell subsets via monoclonal antibodies, the inhibition of intracellular signaling pathways (e.g., calcineurin or JAK inhibition) to suppress activation, or the blockade of immune checkpoints (e.g., PD-1/CTLA-4) to enhance effector functions.